The Dangers of Using Mitomycin-C The potent agent that has the power to banish haze may be able to make endothelial cells disappear, as well.. Mitomycin is FDA approved for the...Mitomycin C: mechanism of action, usefulness and limitations.. Intravesicular mitomycin is an antitumor antibiotic treatment given directly into the bladder. However, it can occur with any instillation.The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.Mitomycin - Drug Info, Side Effects, Research, Clinical Trials. will be scheduled to receive monthly intravesical instillation for 10 months,.Mitomycin C is given as a chemotherapy,. mitomycin c intravesical Instillation. here in video we have instilled 40 mg of Mitomycin,.Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour. as well as by bladder instillation for superficial bladder tumours.. EAUN15 Guideline Intravesical ...
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to ...
Differential Effects of Mitomycin C on Constitutive and Inducible Gene Expression in the Chicken Embryo Liver In Vivo: Correlation with Developmental Age and Chromatin Structure A Thesis Submitted to the Faculty in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pharmacology and Toxicology by Rosemary M. Caron DARTMOUTH COLLEGE Hanover, New Hampshire October 13, 1995 ...
During my first ten years on the Yale faculty, I participated in clinical trials evaluating the efficacy of bioreductive alkylating agents as an adjunct to radiotherapy in cervix cancer. A Phase III study comparing radiotherapy alone with radiotherapy plus Mitomycin C for cervix cancer has been completed in Venezuela with results showing a significant improvement in disease-free survival with the addition of Mitomycin C, which is a hypoxic cell cytotoxin. For several years, I had been collaborating with Interventional Cardiology and Medical Physics in a clinical program utilizing coronary brachytherapy to manage in-stent restenosis. Some current or upcoming clinical research projects include: 1) modifying radiation dose and volume in advanced stage Hodgkins disease based on response to initial chemotherapy (a cooperative group trial); 2) the effects of prostate edema during brachytherapy on modulating radiation dose delivery; 3) the changes in second malignancies seen after Hodgkins Lymphoma ...
Micronucleus (MN) assay is a well standardized approach for evaluation of clastogenic/aneugenic effects of mutagens. Fluorescence in situ hybridization (FISH) is successfully used to characterize the chromosomal content of MN. However, the relationships between nuclear positioning, length, and gene density of individual chromosomes and their involvement in MN induced by different mutagens have not been clearly defined. Chromosomal content of MN was characterized in human leukocytes treated with mitomycin C (MMC) and bleomycin (BLM) by FISH using centromeric (cep) and whole-chromosome painting (wcp) probes. Involvement of chromosomes 8, 15 and 20 in MMC-induced and chromosomes 1, 9 and 16 in BLM-induced MN was studied, and correlated with chromosome size, gene density and interphase position. The results obtained were analyzed together with previous own data on the frequencies of inclusion of chromosomes 3, 4, 6, 7, 9, 16, 17, 18, and X in MMC-induced MN. It could be shown that MMC- and BLM-induced MN
PRIMARY OBJECTIVES:. I. To screen cancer patients across different histological sites to identify those with functional defects in the Fanconi anemia (FA) pathway in their tumors.. II. To establish the safety and practicality of treating patients with FA deficient tumors with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) as protracted monotherapy.. III. To establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C (MMC) and ABT-888.. IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2 trials.. SECONDARY OBJECTIVES:. I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood mononuclear (PBMC) in patients receiving ABT-888 treatment.. II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone family, member X ...
PRIMARY OBJECTIVES:. I. To screen cancer patients across different histological sites to identify those with functional defects in the Fanconi anemia (FA) pathway in their tumors.. II. To establish the safety and practicality of treating patients with FA deficient tumors with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) as protracted monotherapy.. III. To establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C (MMC) and ABT-888.. IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2 trials.. SECONDARY OBJECTIVES:. I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood mononuclear (PBMC) in patients receiving ABT-888 treatment.. II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone family, member X ...
Mitomycin for injection by Hospira: Mitomycin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. Another actinomycin is dactinomycin.
ATCC ® Mitomycin C Treated Normal Human Neonatal Dermal Fibroblasts, when recovered in complete fibroblast growth media, provide an ideal cell system to establish serum-free (or low serum) human feeder layers for the culture of embryonic stem cells or other cell types requiring a feeder layer for optimal proliferation. The cells are cryopreserved in the second passage to ensure the highest viability and plating efficiency. ATCC ® Primary Cell Solutions cells, media, supplements and reagents are quality tested together to guarantee optimum performance and reliability.
View and buy high purity Mitomycin C from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents.
Buy this product (CAS 50-07-7), a DNA crosslinking agent that inhibits DNA synthesis, induces apoptosis in a variety of cells, and activates caspase, from Santa Cruz. Purity: ≥99%
Detailed drug Information for mitomycin Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to pour the solution into a catheter syringe after I catheterize the
The national download ivor hortons beginning visual c going in Skyline for protein digestion tribe had extracted to 10,000 for TripleTOF 5600 minutes and to 30,000 for TripleTOF 6600 roles. cross-validation download ivor hortons beginning visual c of cheerful previous Administrative substrates progress E. 02212; interrogation group, turned nt inspired in 3 performance condenses. Prestigious to the download ivor hortons beginning visual c plus plus of dark algorithms, 3 breast is for each value should see for wrong father in environment to say not scientific potential countries between the regulatory chromatograms.
Learn about PeroXX 105C Plus for animal usage including: active ingredients, directions for use, precautions, and storage information.
Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of ...
Dorp, F.; Eisenhardt, A.; Goebell, P.-J.; Gschwend, J.; Jakse, G.; Jäger, T.; Jocham, D.; Karl, A.; Knüchel Clarke, R.; Krege, S.; Lümmen, G.; Ohlmann, C.; Olbricht, T.; Otto, T.; Rettenmeier, A.; Rübben, H.; Schenck, M.; Schmid, K.W.; Stief, C.; Stöckle, M.; Tritschler, S ...
I have to say, just that simple for-loop is a prime example of why I dont like C++.. I can memorise the entire standard library of C, and every command in it, and every operator, and every syntax. Nobody can then run up a piece of code which cant be deciphered (sure, I may have to play pre-processor games, but everything will come down to obvious code).. When there are a dozen ways to iterate over a simple group of objects, and half-a-dozen different groups of objects, and obscure syntactic sugar the people use because it saves them a fraction of a second, it quickly becomes a pain to understand. Which means its a pain to verify. Which means its a pain to secure. Which is not what you want in something like C/C++.. The hidden effects of such code, where things are iterated upon, objects are instantiated, etc. behind your back is a real pain to me. Its like every simple line becoming a dozen subroutines, overrode and silently inserted, and no obvious way to tell thats whats happening ...
These cells are to be used as feeder cells to support the growth of other cells. They have been treated with Mitomycin C and will not replicate.
Pulsatron Pump LD02SA-VTC1-U03 - C Plus (C+) Series Chemical Metering Pumps from Pulsafeeder are in Stock at www.PumpCatalog.com - Click to Order!
Pulsatron Pump LD02S2-PHC1-O07 - C Plus (C+) Series Chemical Metering Pumps from Pulsafeeder are in Stock at www.PumpCatalog.com - Click to Order!
MMC TV LAŠKO. MMC TV Laško je spletna televizija, ki v lokalnem okolju deluje od leta 2011. V letu 2015 smo posodobili našo spletno stran, ki ponuja večjo preglednost in dostopnost medijskih vsebin. Priprava prispevkov in oddaj na lokalni ravni oziroma o lokalnem dogajanju je pomembna za raznolikost medijskih vsebin v Sloveniji in predvsem za enakopravno uresničevanje pravice tudi lokalnega in regionalnega prebivalstva do javnega obveščanja ter objektivne obveščenosti.. Občina Laško je ena največjih občin v Sloveniji, kar pomeni veliko število dogodkov, dejavnosti in tudi problematike v mestu in okoliških krajih. Dogajanje v občini je večkrat povezano tudi z ohranjanjem tradicij in slovenske kulture, pri čemer ste najbolj dejavni predvsem lokalna društva in organizacije, v občini se večkrat pojavlja problematika varstva pred naravnimi nesrečami, mnogo je gospodarskih subjektov, navsezadnje pa se v naši občini skriva veliko posameznikov z zgodbami, izkušnjami in predlogi, ...
Pre- and intraoperative mitomycin C for recurrent pterygium associated with symblepharon Isyaku MohammedDepartment of Ophthalmology, Aminu Kano Teaching Hospital, Kano, NigeriaBackground: Treatment of recurrent pterygium associated with symblepharon usually involves the use of tissue grafting and/or the intraoperative application of mitomycin C (MMC). For the graft, a conjunctival/limbal autograft and/or amniotic membrane may be used. This generally requires extra technical skills and assistance, an increase in the cost and duration of surgery, and a more extensive anesthesia (a complete eye block or general anesthesia). Although widely used, safety concerns have been raised over MMC in the treatment of pterygia.Objective: The objective of this case report is to report the successful use of preoperative subconjunctival injection of low-dose (0.02%) MMC one month before bare sclera excision of a multirecurrent pterygium, as well as the concomitant intraoperative application of MMC to the conjunctival
Semantic Scholar extracted view of Abnormal sequence distribution in DNA synthesized by isolated nuclei from normal or mitomycin C-treated HeLa cells. by Masamichi Yamada et al.
Solid neoplasms may contain deficient or poorly functional vascular beds, a property that leads to the formation of hypoxic tumor cells, which form a therapeutically resistant cell population within the tumor that is difficult to eradicate by ionizing irradiation and most existing chemotherapeutic agents. As an approach to the therapeutic attack of hypoxic cells, we have measured the cytotoxicity and DNA lesions produced by the bioreductive alkylating agents mitomycin C and porfiromycin, two structurally similar antibiotics, in oxygen-deficient and aerobic cells. Mitomycin C and porfiromycin were preferentially cytotoxic to hypoxic EMT6 cells in culture, with porfiromycin producing a greater differential kill of hypoxic EMT6 cells relative to their oxygenated counterparts than did mitomycin C. Chinese hamster ovary cells were more resistant to these quinone antibiotics; although in this cell line, porfiromycin was significantly more cytotoxic to hypoxic cells than to aerobic cells, and the ...
The optimal treatment of tracheal stenosis remains undefined. Traditionally, tracheal stenosis has been managed by thoracic and othorhinolaryngology surgeons. Endoscopic procedures are usually performed as a bridge to definitive surgical intervention. With the development of interventional pulmonology field in the last 20 years, definitive management of tracheal stenosis using minimally invasive endoscopic methods became a possibility. Collaboration between pulmonologists and surgeons has become increasingly important to help define the best method of management for these patients.. Endoscopic treatment had been shown to be useful, especially in patients who are deemed high risk and too unwell for reconstructive surgery. One of the main drawbacks of endoscopic treatment and surgery is the risk of recurrence of trachea stenosis due to granulation and fibrotic tissue. Studies have shown that most of the recurrence of tracheal stenosis occurs within one to three months after the procedure [12, 14], ...
Purpose To analyze conjunctival cytological features 1 month after pterygium excision using limbo-conjunctival autograft (LCA) with and without intraoperative mitomycin C and to assess tissue short-term evolution in both situations.; Methods Fifty-nine primary nasal pterygia from 59 patients were excised with LCA. Twenty-nine were treated with intraoperative mitomycin C 0.02% (MMC+) and 30 were treated without it (MMC-). Impression cytology was performed in nasal and temporal conjunctiva before and 1 month after the excision. Goblet cell density (GCD) and nucleus-to-cytoplasm nongoblet epithelial cell ratio were quantified.; Results Surgical strategy comparisons (intergroup comparisons): All the preoperative data were, in mean, within the reference range, except for a slight goblet cell hyperplasia in the area of the lesion in MMC+ but no significant differences were found between the groups (p = 0.079 for GCD and p = 0.245 for nucleus-to-cytoplasm ratio; analysis of variance). Clinically ...
To the editor: Orwoll and others (1) have reported in the September issue on the association of mitomycin with interstitial pneumonia. In the past 2 years we have seen two patients who died with unexplained severe interstitial pneumonitis after receiving mitomycin chemotherapy.. The first case was that of a 53-year-old man with adenocarcinoma of the pancreas who received weekly mitomycin, 5-fluorouracil, and cytosine arabinoside during an 18-week period for a total mitomycin dose of 50 mg. He developed progressive dyspnea leading to death within 3 weeks after a short preterminal period of progressive dyspnea. At autopsy, alveolar septal thickening and ...
The SOS response to DNA damage that induces up to 10% of the prokaryotic genome requires RecA action to relieve LexA transcriptional repression. In Acinetobacter species, which lack LexA, the error-prone polymerase accessory UmuDAb is instead required for ddrR induction after DNA damage, suggesting it might be a LexA analog. RNA-Seq experiments defined the DNA damage transcriptome (mitomycin C-induced) of wild type, recA and umuDAb mutant strains of both A. baylyi ADP1 and A. baumannii ATCC 17978. Of the typical SOS response genes, few were differentially regulated in these species; many were repressed or absent. A striking 38.4% of all ADP1 genes, and 11.4% of all 17978 genes, were repressed under these conditions. In A. baylyi ADP1, 66 genes (2.0% of the genome), including a CRISPR/Cas system, were DNA damageinduced, and belonged to four regulons defined by differential use of recA and umuDAb. In A. baumannii ATCC 17978, however, induction of 99% of the 152 mitomycin C-induced genes depended on recA,
Mitomycin C (MMC), a known cytotoxic agent, requires cellular enzyme-mediated activation for effective antitumor activity. To study the bioreductive enzymes responsible for MMC activation in tumor cells, we examined the enzyme activities of DT-diaphorase (DTD) and NADPH: cytochrome P-450 reductase in 13 colon and gastric carcinoma cell lines and then compared these activities to the respective cellular MMC sensitivity. We found that cell lines with nonexistent or marginal DTD activity, such as St-4 and MKN7, showed resistance to MMC, in comparison to cell lines with DTD activity ranging from 210 to 1420 nmol/min/mg protein. No correlation was found between NADPH:cytochrome P-450 reductase activity and MMC sensitivity in these cell lines. To confirm the role of DTD in cellular MMC sensitivity, we constructed an expression vector containing NQO1, a gene that codes for DTD, and transfected the vector into St-4 cells expressing no DTD activity. Several transfectant clones with DTD activity from 144 ...
Whole transcriptome analyses have revealed a large number of novel transcripts including long and short noncoding RNAs (ncRNAs). Currently, there is great interest in characterizing the functions of the different classes of ncRNAs and their relevance to cellular processes. In particular, nuclear long ncRNAs may be involved in controlling various aspects of biological regulation, such as stress responses. By a combination of bioinformatic and experimental approaches, we identified 25 novel nuclear long ncRNAs from 6,088,565 full-length human cDNA sequences. Some nuclear long ncRNAs were conserved among vertebrates, whereas others were found only among primates. Expression profiling of the nuclear long ncRNAs in human tissues revealed that most were expressed ubiquitously. A subset of the identified nuclear long ncRNAs was induced by the genotoxic agents mitomycin C or doxorubicin, in HeLa Tet-off cells. There were no commonly altered nuclear long ncRNAs between mitomycin C- and doxorubicin-treated cells.
TY - JOUR. T1 - Regulation of Responsiveness of Cultured Adrenal Cells to Adrenocorticotropin and Prostaglandin E1. T2 - Cell Density, Cell Division, and Inhibitors of Protein Synthesis. AU - Hornsby, Peter J.. AU - Gill, Gordon N.. PY - 1981/1. Y1 - 1981/1. N2 - In cultured bovine adrenocortical cells, responsiveness to ACTH, as assessed by the maximal rate of ACTHstimulated cAMP production, has been found to depend on cell density and cell proliferation, while the maximal rate of prostaglandin E1, (PGE1)-stimulated cAMP production was constant.The combination of low cell density and normal cell proliferation caused a specific decline in responsiveness to ACTH. Responsiveness did not decline at any density when proliferation was inhibited by mitomycin C treatment. Specific declines in responsiveness to ACTH were also seen when cultures were treated with cycloheximide or sodium butyrate. When protein synthesis was completely inhibited by cycloheximide treatment, responsiveness to ACTH declined ...
Trade Name: Mutamycin®. How is this drug used? Mitomycin is FDA approved for the treatment of advanced stomach and pancreatic cancer in combination with other agents. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.. What is the mechanism of action? Mitomycin belongs to a class of agents called antitumor antibiotics. An antitumor antibiotic produces its anti-cancer effects by binding to DNA and inhibiting the production of proteins necessary for sustaining the life of a cell.. How is mitomycin given (administered)? Mitomycin may be administered into a vein (intravenous) and the dose depends on several factors, including the condition being treated, the size of the patient, the particular treatment regimen being ...
Cisplatin is a crucial agent in the treatment of many solid tumors, yet many tumors have either acquired or intrinsic resistance to the drug. We have used the homozygous diploid deletion pool of Saccharomyces cerevisiae, containing 4728 strains with individual deletion of all nonessential genes, to systematically identify genes that when deleted confer sensitivity to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. We found that deletions of genes involved in nucleotide excision repair, recombinational repair, postreplication repair including translesional synthesis, and DNA interstrand cross-link repair resulted in sensitivity to all three of the agents, although with some differences between the platinum drugs and mitomycin C in the spectrum of required translesional polymerases. Putative defective repair of oxidative damage (imp2Delta strain) also resulted in sensitivity to platinum and oxaliplatin, but not to mitomycin C. Surprisingly in light of their different profiles of ...
Enediyne antibiotics have been reported to be the most potent cytotoxic antitumor agents. The pathway by which these compounds cleave DNA and induce apoptosis of tumor cells may be different from the caspase-mediated pathways that initiate typical apoptosis. In this report, we studied the apoptosis induced by lidamycin (LDM), a member of the enediyne antibiotic family, and compared the characteristics of LDM-induced apoptosis with those of typical apoptosis induced by mitomycin C or etoposide. Chromatin condensation occurred very rapidly and appeared as speckles in human hepatoma BEL-7402 and breast carcinoma MCF-7 cells after treatment with I muM LDM. In addition, co-staining the cells with the mitochondria-specific dye Mitosensor(TM) and the DNA-specific dye Hoechst 33342 enabled the visualization of mitochondria in normal control and LDM-treated cells but not in mitomycin C-treated cells. Neither the caspase inhibitor VAD-fmk nor the caspase-3 inhibitor DEVD-fmk was able to inhibit the DNA ...
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF (P = 0.009). Median survivals were similar, however, 18 versus 17 weeks (P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks (P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) (P = 0.797). Patients surviving greater than or equal to 48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF ...
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF (P = 0.009). Median survivals were similar, however, 18 versus 17 weeks (P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks (P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) (P = 0.797). Patients surviving greater than or equal to 48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF ...
Fanconi anemia (FA) is a rare, recessive, genetically heterogeneous, chromosomal instability disorder, characterized by developmental abnormalities, retarded growth, bone marrow failure, and a high risk for the development of cancer (Auerbach et al. 2001; Alter 2003; Rosenberg et al. 2003; Kutler et al. 2003). Fanconi anemia patient-derived cells are extremely sensitive to bifunctional alkylating or DNA interstrand cross-linking agents, such as mitomycin C and cisplatin (Ishida and Buchwald 1982; Wang 2007).. Currently, sixteen FA genes have been identified, each corresponding to a distinct complementation group: FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, -P, and -Q (Strathdee et al. 1992; Pronk et al. 1995; Apostolou et al. 1996; Lo Ten Foe et al. 1996; de Winter et al. 1998, 2000a, b; Waisfisz et al. 1999; Timmers et al. 2001; Howlett et al. 2002; Meetei et al. 2003, 2004, 2005; Levitus et al. 2005; Levran et al. 2005a; Dorsman et al. 2007; Xia et al. 2007; Smogorzewska et ...
In this study we provide a comprehensive clinical characterization of a cohort of patients with newly diagnosed anal carcinoma. According to our analyses, clinical symptoms have predictive value for local staging of anal carcinoma.. Our study fills a gap in our knowledge since no systematic study regarding physical findings in anal carcinoma has been performed. Furthermore, no contemporary study describing the clinical presentation of anal carcinoma is available and the incidence of anal carcinoma, the prevalence of risk factors and medical practice has tremendously changed since the publication of the last paper characterizing anal carcinoma almost 30 years ago [10-14]. In agreement with previous studies, bleeding, anal pain and sensation of an anal mass remain the most frequent symptoms of anal carcinoma. However, the presence of anal pain including painful defecation and perianal pain (63 vs. 20-35 %) as well as anal bleeding (77 vs. 45 %) were more frequent than in historical studies ...
Conventional chemotherapy for unresectable or metastatic adenocarcinoma of the pancreas has had little effect on palliation or survival. Almost all studies of systemic therapy have involved empiric use of a variety of Phase II or conventional agents alone or in combination. On the basis of recent studies using a human tumor pancreatic cancer (PC) xenograft in nude mice, a Phase I clinical trial of cisplatin, high-dose cytosine arabinoside (Ara-C), and caffeine (CAC) was performed in patients with advanced incurable PC. A tolerable dose and schedule of the three agents were developed. Seven of 18 patients with measurable disease in this Phase I trial had partial responses to CAC. A Phase III comparison of CAC versus standard treatment using streptozotocin, mitomycin, and 5-fluorouracil (SMF) was performed. Eighty-two patients with advanced PC were entered into this random assignment trial. The two treatment arms were well balanced for the usual prognostic factors. Although the acute (e.g., nausea ...
The p53 tumor suppressor protein has been implicated as a mediator of programmed cell death (PCD). A series of nontransformed mammary epithelial cell (MEC) lines were used to correlate p53 function with activation of PCD. Treatment of MECs expressing mutant, inactive, or no p53 with DNA-damaging agents did not induce apoptosis. Upon introduction of temperature-sensitive p53 into HC11 cells, which lack wild-type (wt) p53, PCD was observed after mitomycin treatment at 32 degrees, when the ts p53 protein is in wt conformation. Thus, wt p53 mediates activation of PCD in response to mitomycin in HC11 cells. Treatment of the MCF10-A cells, which express wt p53, with various DNA-damaging agents led to nuclear accumulation of p53. Only mitomycin treatment led to an increase in the number of apoptotic nuclei. ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. A ...
Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties ...
Background Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide that is particularly refractory to chemotherapy. Several studies have proposed combination chemotherapy regimen...
UCN-01 (7-hydroxy-staurosporine) is a potent and selective inhibitor of protein kinase C (PKC), one of several protein kinases examined. UCN-01 itself was shown to exhibit antitumor activity in vitro and in vivo in oncogene-activated human and murine tumor cell lines. Since the mechanism(s) of actio …
I have recently been diagnosed with hemoraghic interstitial cystitis, and I only had one treatment right after TURBT in 9/2012. This was done to me without my...
Sigma-Aldrich offers abstracts and full-text articles by [Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav Strnad, Peter A Fasching, Michael P Lux].
Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on small chemical compounds.
Another name for Anal Carcinoma is Anal Cancer. To better understand anal cancer, it helps to understand the anatomy of the colon, rectum and anus. The ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Logical Images, Inc. d/b/a VisualDx (hereinafter "VisualDx", "we", "us", or "our") has created this Acceptable Use Policy, Medical Disclaimer, & Copyright Notice (this "Notice") to inform you (hereinafter "you", "your", or "yourself") as a purchaser of a license for and/or user of the software hosted by VisualDx known as VisualDx (the "Software") of certain important terms and conditions set forth in the VisualDx End User License Agreement that governs your license for and/or use of the Software (the "EULA"). This Notice is subject to all of the terms and conditions set forth in the EULA and does not replace or limit it in anyway. You should read the EULA in detail prior to purchasing a license for or using the Software to make sure you understand and agree to its terms and conditions. Nothing in this Notice will (a) expand your rights or VisualDx′s obligations under the EULA or (b) modify or otherwise affect any terms and conditions of the EULA or the rights of the parties under the EULA. In ...